VALBY, Denmark, October 1, 2026
H. Lundbeck A/S announced headline results from the Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) in adults with migraine who had an inadequate response to a previous preventive therapy targeting the calcitonin gene-related peptide (CGRP) pathway. The randomized clinical trial was designed to assess the effectiveness of eptinezumab in a patient population with an unmet need for additional preventive treatment options. According to Lundbeck, THRIVE met its primary endpoint, demonstrating a statistically significant reduction in monthly migraine days during the first 12 weeks of treatment compared with placebo. The results add to the clinical evidence supporting VYEPTI as a preventive treatment for migraine, particularly among patients who have previously received another CGRP-targeting preventive therapy without achieving adequate disease control. Lundbeck said detailed findings from the study will be presented at an upcoming scientific meeting and submitted for publication.
THRIVE Evaluates Patients After Prior CGRP Therapy
The Phase IV THRIVE study was designed to address an important clinical question: whether patients who do not achieve sufficient benefit from one CGRP-targeting preventive treatment may respond to a different therapy directed at the same biological pathway. The trial enrolled adults living with migraine who had experienced an inadequate response to a prior CGRP-targeting preventive therapy. Participants received VYEPTI or placebo, with the study assessing changes in migraine frequency and other measures of treatment effectiveness. The primary endpoint focused on the change from baseline in monthly migraine days (MMDs) over the initial 12-week treatment period. Lundbeck reported that VYEPTI achieved a statistically significant improvement compared with placebo, supporting further evaluation of eptinezumab in this treatment-experienced population. The company said the detailed clinical dataset will provide additional information about treatment response and other outcomes when fully presented.
Eptinezumab Provides Preventive CGRP Targeting
VYEPTI (eptinezumab) is a humanized monoclonal antibody designed to bind to CGRP, a neuropeptide involved in migraine pathophysiology. By binding to CGRP, eptinezumab prevents the peptide from activating its receptors and is intended to reduce the biological processes associated with migraine attacks. Unlike oral preventive medicines that require daily administration, VYEPTI is administered as an intravenous infusion once every three months, providing continuous exposure between treatment visits. The therapy is approved in several markets for the preventive treatment of migraine in adults. Its clinical development program has evaluated eptinezumab across different migraine populations, including patients with episodic and chronic migraine. The THRIVE results extend Lundbeck’s clinical development efforts into patients who have already received preventive therapies targeting the CGRP pathway.
Advertisement
Results Add Evidence for Treatment-Experienced Patients
The THRIVE findings are relevant to migraine management because a proportion of patients do not obtain adequate control with their first preventive treatment. Switching preventive therapies is a common component of long-term migraine management, and clinical data in patients who have previously received CGRP-targeting treatments can help inform treatment decisions. Lundbeck said the study met its primary endpoint, while further analyses are expected to provide more information regarding secondary endpoints and the broader efficacy and safety profile of VYEPTI in this patient population. The company plans to communicate the detailed findings through a future scientific presentation and publication. Migraine is a neurological disease characterized by recurrent attacks that can include moderate to severe headache, nausea, and sensitivity to light and sound, with substantial effects on daily activities and quality of life. Preventive therapies aim to reduce the frequency and severity of attacks and the need for acute treatment. The THRIVE study therefore contributes additional evidence regarding the potential role of eptinezumab after inadequate response to previous CGRP-targeting prevention. As the complete results become available, additional analyses may help clarify the magnitude and consistency of treatment response, safety findings and other clinically relevant outcomes.
Source: Lundbeck press release
